BeOne Medicines Ltd. (NASDAQ:ONC) is one of the high-growth large-cap stocks to invest in. On June 11, BeOne Medicines Ltd. (NASDAQ:ONC) presented updated Phase 3 clinical data at the European Hematology Association Congress for its approved BTK inhibitor, BRUKINSA.
Dragon Images/Shutterstock.com
The company markets BRUKINSA as a targeted prescription medication for the treatment of various types of B-cell blood cancers in adults. The oral small molecule inhibitor of Bruton’s tyrosine kinase (BTK) is designed to deliver complete and sustained inhibition of the BTK protein. It is currently approved in 80 markets.
The study results showed sustained benefit from the use of the drug to treat chronic lymphocytic leukemia or small lymphocytic lymphoma. The 78-month SEQUOIA data showed progression-free survival of 71.8% with the drug, compared with 31% with bendamustine-rituximab. The safety profile in the Phase 3 trial was also consistent with previous studies. The study results reinforced BRUKINSA’s role as a foundational BTK inhibitor after nearly 6.5 years of follow-up.
BeOne Medicines Ltd. (NASDAQ:ONC) is a global biopharmaceutical company dedicated to discovering, developing, and delivering innovative, affordable, and accessible cancer treatment.
While we acknowledge the potential of ONC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 12 High-Growth Micro-Cap Stocks to Buy Now and 10 Best Long-Term Stocks to Invest In According to Bill & Melinda Gates Foundation Trust.
Disclosure: None. Follow Insider Monkey on Google News.
